...
首页> 外文期刊>Journal of Neuropathology and Experimental Neurology >Leucine-Rich Repeat Kinase 2 Expression Leads to Aggresome Formation That Is Not Associated With [alpha]-Synuclein Inclusions
【24h】

Leucine-Rich Repeat Kinase 2 Expression Leads to Aggresome Formation That Is Not Associated With [alpha]-Synuclein Inclusions

机译:富含亮氨酸的重复激酶2表达导致与α-突触核蛋白包涵体不相关的聚集体形成

获取原文
获取原文并翻译 | 示例
           

摘要

Mutations in leucine-rich repeat kinase-2 (LRRK2) are the most common known cause of Parkinson disease, but how this protein results in the pathobiology of Parkinson disease is unknown. Moreover, there is variability in pathology among cases, and alpha-synuclein (alpha-syn) neuronal inclusions are often present, but whether LRRK2 is present in these pathological inclusions is controversial. This study characterizes novel LRRK2 antibodies, some of which preferentially recognize an aggregated form of LRRK2, as observed in cell culture models. Large perinuclear aggregates containing LRRK2 were promoted by proteasome inhibition and prevented by microtubule polymerization inhibition. Furthermore, they were vimentin- and gamma-tubulin- but not lamp1-immunoreactive, suggesting that these structures fit the definition of aggresomes. Inhibition of heat shock protein 90 led to the degradation of only the soluble/cytosolic pool of LRRK2, suggesting that the aggresomes formed independent of the stability provided by the heat shock protein 90. Although these novel anti-LRRK2 antibodies identified aggregates in model cell systems, they did not immunostain pathological inclusions in human brains. Furthermore, coexpression of LRRK2 and alpha-syn did not recruit alpha-syn into aggresomes in cultured cells, even in the presence of proteasome inhibition. Thus, although LRRK2 is a model system for aggresome formation, LRRK2 is not present in alpha-syn pathological inclusions.
机译:富含亮氨酸的重复激酶2(LRRK2)中的突变是帕金森氏病的最常见已知病因,但该蛋白如何导致帕金森氏病的病理生物学尚不清楚。此外,病例之间的病理学也存在差异,通常会出现α-突触核蛋白(α-syn)神经元包涵体,但是在这些病理性包涵体中是否存在LRRK2仍存在争议。这项研究的特征是新型LRRK2抗体,其中一些优先识别LRRK2的聚集形式,如在细胞培养模型中观察到的那样。蛋白酶体抑制促进含有LRRK2的大核周聚集体,而微管聚合抑制则阻止大的核周聚集体。此外,它们是波形蛋白和γ-微管蛋白,而不是lamp1免疫反应活性,表明这些结构符合聚集体的定义。抑制热激蛋白90仅导致LRRK2的可溶性/胞质池降解,这表明聚集体的形成与热激蛋白90的稳定性无关。尽管这些新型抗LRRK2抗体鉴定了模型细胞系统中的聚集体。 ,他们没有免疫染色人脑中的病理性内含物。此外,即使存在蛋白酶体抑制作用,LRRK2和α-syn的共表达也不会在培养细胞的聚集体中募​​集α-syn。因此,尽管LRRK2是聚集体形成的模型系统,但LRRK2不存在于alpha-syn病理性包涵体中。

著录项

  • 来源
  • 作者单位

    Elisa A. Waxman, PhD, Jason P. Covy, BS, Irene Bukh, BS, Xiaojie Li, MSc, Ted M. Dawson, MD, PhD, and Benoit I. Giasson, PhDFrom the Department of Pharmacology (EAW, JPC, IB, BIG), University of Pennsylvania, Philadelphia, Pennsylvania, NeuroRegeneration and Stem Cell Programs (XL), Institute for Cell Engineering, and Graduate Program in Cellular and Molecular Medicine (XL, TMD), Departments of Neurology (TMD) and Solomon H. Snyder Department of Neuroscience (TMD), Johns Hopkins University School of Medicine, Baltimore, Maryland.Send correspondence and reprint requests to: Benoit I. Giasson, PhD, Department of Pharmacology, University of Pennsylvania School of Medicine, 3620 Hamilton Walk, 125 John Morgan Building, Philadelphia, PA 19104-6084, E-mail: giassonb@mail.med.upenn.eduThis work was funded by grants from the National Institute on Aging (AG09215), the National Institute of Neurological Disorders and Stroke (NS053488 and NS38377), and The Ellison Medical Foundation. E.A.W. was supported by a training grant (T32 AG00255) from the National Institute on Aging. The Biomedical Imaging Core Lab is supported by Abramson Cancer Institute at the University of Pennsylvania.,;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号